Table 3. Quantitative analysis of 25 (OH) vitD levels in MS patients and controls.
| 25 (OH) Vitamin D levels [Mean (SD)] | p-value | |||
|---|---|---|---|---|
| MS patients versus | ||||
| Disease | nmol/L | MS group<br>(n=108)<br>26 (24) | Healthy Controls<br>(n=210)<br>34.75 (21.1) | 0.002 |
| Gender | nmol/L | Female patients<br>(n=77)<br>18.75 (13.75) | Female controls<br>(n=145)<br>25.05 (15.25) | 0.003 |
| nmol/L | Male patients<br>(n=31)<br>44.5 (33.25) | Male Controls<br>(n=65)<br>56.15 (15.75) | 0.023 | |
| MS subgroups | ||||
| Gender | nmol/L | Female patients<br>(n=77)<br>18.75 (13.75) | Male patients<br>(n=31)<br>44.5 (33.25) | <0.001 |
| MS clinical form | nmol/L | RR-MS<br>24.02 (20) | progressive MS<br>25.65 (16.75) | 0.76 |
| IgG Index | nmol/L | Low (<0.7)<br>29 (23.25) | High (>0.7)<br>22.8 (16.75) | 0.26 |
| OCB profile in CSF | nmol/L | OCB Positive MS<br>24.65 (20.25) | OCB Negative MS<br>23 (15.25) | 0.71 |
| Intrathecal Synthesis<br>of IgG | nmol/L | Positive<br>22.5 (16.75) | Negative<br>29.9 (23.5) | 0.19 |
| Needed Treatment | nmol/L | Interféron β-1b26.9 (25.5) | Natalizumab<br>22.75 (16.5) | 0.45 |